Please assess the completion status of the following clinical trial:

Trial Title: The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide informed consent.~2. Not pregnant~3. Willing to participate in follow up as part of the study~4. Diagnosis of MDD and/or GAD by MINI~5. Current depressive episode with a MADRS score of ≥15 or Current GAD episode with GAD-7 score of ≥8.~6. Able to understand and comply with the requirements of the study~7. Able to provide stool and blood samples.~Exclusion Criteria:~1. History of chronic diarrhea~2. Need for regular use of agents that affect GI motility (narcotics such as codeine or morphine, agents such as loperamide or metoclopramide)~3. Colostomy~4. Elective surgery that will require preoperative antibiotics planned within 6 months of enrolment~5. Pregnant, breastfeeding, or planning to get pregnant in the next 6 months~6. Any condition for which, in the opinion of the investigator, the participant should be excluded from the study.~7. Current use of any antidepressant/antianxiety drug (eligible to participate after a 4-week washout period)~8. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a 1-month washout period)~9. History of alcohol or substance dependence in the past 6 months~10. Daily use of probiotic product in the past 2 weeks (may be eligible to participate after a 2-week washout period)~11. Use of any type of laxative in the last 2 weeks.~12. Consumption of products fortified in probiotics~13. High suicidal risk, as measured by MADRS item 10 score more than 3 (or 4)~14. Current psychotic symptoms~15. Bipolar Depression~16. History of epilepsy or uncontrolled seizures~17. Immunodeficiency (immuno-compromised and immuno-suppressed participants; e.g. acquired immune deficiency syndrome \[AIDS\], lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants)~18. Unstable medical conditions or serious diseases/conditions (e.g. cancer, cardiovascular, renal, lung, diabetes, psychiatric illness, bleeding disorders, etc.)~19. The use of natural health products (Natural health products \[NHPs\]; e.g. St. John's Wort, passion flower, etc.) that affect depression~20. History of Electroconvulsive therapy (ECT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Major Depression Disorder (Type: EXPERIMENTAL): MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
- Generalized Anxiety Disorder (Type: EXPERIMENTAL): MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured

Based on this trial design, predict the completion outcome and termination type (if applicable).